Featured Research

from universities, journals, and other organizations

Hormonal Male Contraception Reversible After Few Months For All Men

Date:
April 28, 2006
Source:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed)
Summary:
With hormonal male contraception likely to be available in the near future, results of a study in this week's issue of The Lancet highlight how such contraception is reversible within a few months.

With hormonal male contraception likely to be available in the near future, results of a study in this week's issue of The Lancet highlight how such contraception is reversible within a few months.

Currently available male contraceptive methods (condoms, withdrawal, and vasectomy) are not acceptable to many couples because they are either not sufficiently reliable or not easily reversible. In a similar way to ovulation suppression by hormone treatment in women, sperm production can be fully inhibited by androgen or androgen-progestagen treatment combinations in men. With such hormone treatment, azoospermia (no sperm in ejaculate) or severe oligozoospermia (less than 3 million sperm per mL of semen), which is sufficient for contraceptive purposes, can be achieved. Currently, a large phase III study with an androgen treatment and a large, multicentre phase II study of androgen-progestagen combinations are being completed in China and Europe, respectively.

Peter Liu from the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), who is currently located at the ANZAC Research Institute, University of Sydney, Australia, and colleagues analysed data from individual participants in 30 studies published in 1990-2005, in which sperm output was monitored every month until recovery. The primary outcome was the time for the sperm concentration to recover to a threshold of 20 million per mL, an indicator of fertility.

Data were available for around 1500 men. The average time for sperm recovery to 20 million/mL was 3.4 months. Various factors were associated with higher rates of recovery including older age, Asian origin, shorter treatment duration, and higher sperm concentrations at baseline. Although these factors modulated the speed of recovery, spermatogenesis recovered to levels compatible with fertility in all men.

Dr Liu and colleagues comment: "Our data provide strong assurance that the previously described efficacy of hormonal male contraceptives is coupled with highly predictable recovery to semen characteristics that are compatible with fertility. These findings thereby increase the promise of new contraceptive drugs allowing men to share more fairly the satisfaction and burden of family planning."

The Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed) is one of the largest independent, not-for-profit biomedical research institutes in Los Angeles County. Affiliated with both the David Geffen School of Medicine at UCLA and the Harbor-UCLA Medical Center, the Institute has an annual budget of over $72 million and currently supports more than 1,000 research studies in areas such as cardiology, emerging infections, cancer, women's health, reproductive health, vaccine research, respiratory physiology, neonatology, molecular biology, and genetics.


Story Source:

The above story is based on materials provided by Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). Note: Materials may be edited for content and length.


Cite This Page:

Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). "Hormonal Male Contraception Reversible After Few Months For All Men." ScienceDaily. ScienceDaily, 28 April 2006. <www.sciencedaily.com/releases/2006/04/060428151836.htm>.
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). (2006, April 28). Hormonal Male Contraception Reversible After Few Months For All Men. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2006/04/060428151836.htm
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed). "Hormonal Male Contraception Reversible After Few Months For All Men." ScienceDaily. www.sciencedaily.com/releases/2006/04/060428151836.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins